N-(1-carbamoyl-2-phenylethyl) butyramide reduces antibiotic-induced intestinal injury, innate immune activation and modulates microbiota composition (182 views visite)
Sci Rep (ISSN: 2045-2322linking, 2045-2322electronic), 2019 Mar 18; 9(1): 4832-4832.
Export to Esporta in BibTeX Export to Esporta in EndNote
Paper type Tipo di articolo: Journal Article
Impact factor: 5.078, 5-year impact factor Impact factor a 5 anni: 5.078
Url: Not available. Non disponibile.
Keywords Parole chiave: Acetylation Drug Effects , Animals , Anti-Bacterial Agents Adverse Effects , Bacterial Translocation Drug Effects , Butyrates Administration, Dosage Metabolism , Ceftriaxone Adverse Effects , Colitis Chemically Induced Drug Therapy Immunology Microbiology , Colon Drug Effects Immunology Microbiology Pathology , Disease Models, Dysbiosis Chemically Induced Drug Therapy Immunology Microbiology , Gastrointestinal Microbiome Drug Effects , Histones Metabolism , Humans , Immunity, Innate Drug Effects , Intestinal Mucosa Drug Effects Immunology Microbiology Pathology , Lactic Acid Metabolism , Monocarboxylic Acid Transporters Metabolism , Receptors, G-Protein-Coupled Metabolism , Symporters Metabolism
Affiliations Affiliazioni:
*** IBB - CNR ***
Department of Pharmacy, University of Naples "Federico II", Via D. Montesano 49, 80131, Naples, Italy.
Task Force on Microbiome Studies, University of Naples "Federico II", Via D. Montesano 49, 80131, Naples, Italy.
Institute for Experimental Endocrinology and Oncology, IEOS, Via S. Pansini 5, 80131, Naples, Italy.
Department of Biology, University of Naples "Federico II", Cupa Nuova Cinthia 21, 80126, Naples, Italy.
Department of Molecular Medicine and Medical Biotechnology, University of Naples "Federico II", Via S. Pansini 5, 80131, Naples, Italy.
Department of Advanced Biomedical Sciences, University of Naples "Federico II", Via S. Pansini 5, 80131, Naples, Italy.
Institute of Biostructure and Bioimaging, Consiglio Nazionale delle Ricerche CNR, Via S. Pansini 5, 80131, Naples, Italy.
References Riferimenti:
Not available. Non disponibili.
Sci Rep (ISSN: 2045-2322linking, 2045-2322electronic), 2019 Mar 18; 9(1): 4832-4832.
Export to Esporta in BibTeX Export to Esporta in EndNote
Paper type Tipo di articolo: Journal Article
Impact factor: 5.078, 5-year impact factor Impact factor a 5 anni: 5.078
Url: Not available. Non disponibile.
Keywords Parole chiave: Acetylation Drug Effects , Animals , Anti-Bacterial Agents Adverse Effects , Bacterial Translocation Drug Effects , Butyrates Administration, Dosage Metabolism , Ceftriaxone Adverse Effects , Colitis Chemically Induced Drug Therapy Immunology Microbiology , Colon Drug Effects Immunology Microbiology Pathology , Disease Models, Dysbiosis Chemically Induced Drug Therapy Immunology Microbiology , Gastrointestinal Microbiome Drug Effects , Histones Metabolism , Humans , Immunity, Innate Drug Effects , Intestinal Mucosa Drug Effects Immunology Microbiology Pathology , Lactic Acid Metabolism , Monocarboxylic Acid Transporters Metabolism , Receptors, G-Protein-Coupled Metabolism , Symporters Metabolism
Affiliations Affiliazioni:
*** IBB - CNR ***
Department of Pharmacy, University of Naples "Federico II", Via D. Montesano 49, 80131, Naples, Italy.
Task Force on Microbiome Studies, University of Naples "Federico II", Via D. Montesano 49, 80131, Naples, Italy.
Institute for Experimental Endocrinology and Oncology, IEOS, Via S. Pansini 5, 80131, Naples, Italy.
Department of Biology, University of Naples "Federico II", Cupa Nuova Cinthia 21, 80126, Naples, Italy.
Department of Molecular Medicine and Medical Biotechnology, University of Naples "Federico II", Via S. Pansini 5, 80131, Naples, Italy.
Department of Advanced Biomedical Sciences, University of Naples "Federico II", Via S. Pansini 5, 80131, Naples, Italy.
Institute of Biostructure and Bioimaging, Consiglio Nazionale delle Ricerche CNR, Via S. Pansini 5, 80131, Naples, Italy.
References Riferimenti:
Not available. Non disponibili.
N-(1-carbamoyl-2-phenylethyl) butyramide reduces antibiotic-induced intestinal injury, innate immune activation and modulates microbiota composition
The use/misuse of antibiotics leads to pathological features referring to antibiotic-induced intestinal injury (AIJ), a clinical issue that plays a prominent role in the development of severe digestive disturbances. AIJ is characterized by loss of intestinal architecture and function, dysbiosis and bacterial translocation into the liver, triggering hepatic inflammation. This study aimed at determining the beneficial effect of N-(1-carbamoyl-2-phenylethyl) butyramide (FBA), a butyrate releasing compound, in ceftriaxone-induced intestinal injury. To this purpose, mice receiving ceftriaxone (8 g∙kg(-1)/die, per os) for five days, were treated with FBA (212,5 mg∙kg(-1)/die, per os) for five or fifteen days. FBA modulated key players of innate immunity in antibiotic-injured gut tissues, reducing inflammatory process and improving the anti-inflammatory and resolving pattern. FBA also improved colonic architecture and intestinal integrity. Interestingly, we also observed a remodeling of gut microbiota composition related to an increase of metabolic pathways related to lactate and butyrate production. At mechanistic level, FBA induced histone acetylation and increased the expression of GPR43 and monocarboxylate transporter 1 in colon. Our data clearly demonstrated that FBA has multiple converging mechanisms in limiting intestinal and hepatic alterations to counteract AIJ.
The use/misuse of antibiotics leads to pathological features referring to antibiotic-induced intestinal injury (AIJ), a clinical issue that plays a prominent role in the development of severe digestive disturbances. AIJ is characterized by loss of intestinal architecture and function, dysbiosis and bacterial translocation into the liver, triggering hepatic inflammation. This study aimed at determining the beneficial effect of N-(1-carbamoyl-2-phenylethyl) butyramide (FBA), a butyrate releasing compound, in ceftriaxone-induced intestinal injury. To this purpose, mice receiving ceftriaxone (8 g∙kg(-1)/die, per os) for five days, were treated with FBA (212,5 mg∙kg(-1)/die, per os) for five or fifteen days. FBA modulated key players of innate immunity in antibiotic-injured gut tissues, reducing inflammatory process and improving the anti-inflammatory and resolving pattern. FBA also improved colonic architecture and intestinal integrity. Interestingly, we also observed a remodeling of gut microbiota composition related to an increase of metabolic pathways related to lactate and butyrate production. At mechanistic level, FBA induced histone acetylation and increased the expression of GPR43 and monocarboxylate transporter 1 in colon. Our data clearly demonstrated that FBA has multiple converging mechanisms in limiting intestinal and hepatic alterations to counteract AIJ.
N-(1-carbamoyl-2-phenylethyl) butyramide reduces antibiotic-induced intestinal injury, innate immune activation and modulates microbiota composition
No results. Nessun risultato. |
N-(1-carbamoyl-2-phenylethyl) butyramide reduces antibiotic-induced intestinal injury, innate immune activation and modulates microbiota composition
Caraci F, Bruno V, Copani A, Matrisciano F, Nicoletti F, Battaglia G
* The impact of metabotropic glutamate receptors into active neurodegenerative processes: A "dark side" in the development of new symptomatic treatments for neurologic and psychiatric disorders (266 visite)
Neuropharm (ISSN: 0028-3908, 1873-7064electronic, 0028-3908linking), 2017 Mar 15; 115: 180-192.
Impact Factor: 5.012
Dettagli Esporta in BibTeX Esporta in EndNote
1 Records (1 escludendo Abstract e Conferenze).
Impact factor totale: 5.012 (5.012 escludendo Abstract e Conferenze).
Impact factor a 5 anni totale: 4.681 (4.681 escludendo Abstract e Conferenze).
Vai a fine pagina Versione per copia e incolla facile Esporta tutto in BibTeX Esporta tutto in EndNote
Caraci F, Bruno V, Copani A, Matrisciano F, Nicoletti F, Battaglia G
* The impact of metabotropic glutamate receptors into active neurodegenerative processes: A "dark side" in the development of new symptomatic treatments for neurologic and psychiatric disorders (266 visite)
Neuropharm (ISSN: 0028-3908, 1873-7064electronic, 0028-3908linking), 2017 Mar 15; 115: 180-192.
Impact Factor: 5.012
Dettagli Esporta in BibTeX Esporta in EndNote
1 Records (1 escludendo Abstract e Conferenze).
Impact factor totale: 5.012 (5.012 escludendo Abstract e Conferenze).
Impact factor a 5 anni totale: 4.681 (4.681 escludendo Abstract e Conferenze).
Last modified by Ultima modifica di Marco Comerci on in data Wednesday 02 December 2020, 18:09:00
182 views visite. Last view on Ultima visita in data Thursday 17 June 2021, 14:48:46
ibb.cnr.it